7 active not recruiting, 5 recruiting, 3 completed, 2 terminated. 19 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Active not recruiting 7, Recruiting 5, Completed 3, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow niraparib: new trials by email Literature Review of niraparib trials Research Report on niraparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-10-30 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Niraparib, Temozolomide - Glioblastoma, GBM | Phase 3 | Active not recruiting | Ivy Brain Tumor Center | 450 | 2024-06-19 | 2026-07-01 |
| Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer Carboplatin, Paclitaxel, Bevacizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | AGO Study Group | 970 | 2022-09-13 | 2025-09-10 |
| Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease Niraparib, Placebo - Neoplasms, Breast | Phase 3 | Active not recruiting | GlaxoSmithKline | 40 | 2021-06-28 | 2025-07-16 |
| Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment Niraparib, Dostarlimab, Pegylated liposomal doxorubicin - Ovarian Cancer | Phase 3 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 427 | 2020-12-01 | 2021-08-27 |
| A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy - Endometrial Carcinoma, P53 Mutation | Phase 2 / Phase 3 | Terminated | University Health Network, Toronto | 11 | 2020-11-17 | 2025-08-12 |
| Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer Niraparib, Pembrolizumab, Placebo - Lung Cancer, Non-Small Cell | Phase 3 | Completed | GlaxoSmithKline | 666 | 2020-10-26 | 2026-06-18 |
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs - Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | Phase 2 / Phase 3 | Recruiting | ARCAGY/ GINECO GROUP | 138 | 2020-07-15 | 2026-09-09 |
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer Niraparib, Bevacizumab, TSR042 - Ovarian Cancer | Phase 3 | Withdrawn | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2019-12-01 | 2021-07-15 | |
| A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer Dostarlimab, Placebo matching dostarlimab, Carboplatin - Neoplasms | Phase 3 | Active not recruiting | Tesaro, Inc. | 785 | 2019-07-18 | 2025-09-03 |
| A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study Atezolizumab, Bevacizumab, Alectinib - Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1000 | 2019-02-28 | 2026-10-22 |
| ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin - Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | Karolinska Institutet | 750 | 2019-02-01 | 2025-04-09 |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer Niraparib, Abiraterone Acetate, Prednisone - Castration-Resistant Prostatic Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 765 | 2019-01-25 | 2026-11-03 |
| Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer Placebo, Carboplatin, Paclitaxel - Recurrent Ovarian Carcinoma | Phase 3 | Completed | Grupo Español de Investigación en Cáncer de Ovario | 417 | 2018-11-21 | 2024-08-30 |
| A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer Niraparib, Dostarlimab (TSR-042), Standard of care - Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Phase 3 | Active not recruiting | Tesaro, Inc. | 1400 | 2018-10-11 | 2025-12-31 |
| A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Niraparib, Placebo - Ovarian Neoplasms | Phase 3 | Active not recruiting | Tesaro, Inc. | 733 | 2016-07-11 | 2026-03-10 |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients niraparib, Physician's choice - Neoplasms, Breast, Carcinoma of Breast | Phase 3 | Terminated | Tesaro, Inc. | 216 | 2014-02-25 | 2022-11-15 |
| A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Active comparator: Niraparib, placebo - Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer | Phase 3 | Completed | Tesaro, Inc. | 596 | 2013-06-21 | 2023-06-02 |
Ovarian Neoplasms (9) · Breast Neoplasms (2) · Fallopian Tube Neoplasms (2) · Neoplasms (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Cystadenocarcinoma, Serous (1) · Endometrial Neoplasms (1) · Glioblastoma (1) · Prostatic Neoplasms, Castration-Resistant (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1)
Tesaro, Inc. (5) · GlaxoSmithKline (2) · AGO Study Group (1) · ARCAGY/ GINECO GROUP (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Grupo Español de Investigación en Cáncer de Ovario (1) · Hoffmann-La Roche (1) · Imunon (1) · Ivy Brain Tumor Center (1) · Janssen Research & Development, LLC (1) · Karolinska Institutet (1) · Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1) · UNICANCER (1) · University Health Network, Toronto (1)
Italy (13) · Belgium (12) · France (12) · Spain (12) · Germany (11) · United States (11) · United Kingdom (10) · Norway (9) · Canada (8) · Poland (8) · Hungary (7) · Israel (7) · Netherlands (7) · Denmark (6) · Sweden (6)
Amit Oza, MD (1) · Ashkan Mortezavi, MD, PhD (1) · Ivan Borbath, MD (1) · Jan Oldenburg, Professor (1) · Johan Lindberg, PhD (1) · John Bridgewater, MD (1) · Juan W Valle (1) · Julien Edeline, MD (1)
PMID 39019698, PMID 29767688, PMID 30026000, PMID 31173551, PMID 31518175, PMID 31562799, PMID 32586393, PMID 32981695, PMID 33318079, PMID 34478166, PMID 34607820, PMID 35170751, PMID 35317973, PMID 35550709, PMID 36172173, PMID 36952634, PMID 36972026, PMID 37185961, PMID 37263896, PMID 37411031, PMID 37731489, PMID 37935524, PMID 38325276, PMID 38431043, PMID 38501262, PMID 38833992, PMID 38950925, PMID 38958846, PMID 38990090, PMID 39013265, PMID 39111209, PMID 39164518, PMID 39292975, PMID 39317633, PMID 39322611, PMID 39346117, PMID 39581729, PMID 40016438, PMID 40263079, PMID 40616865, PMID 42015879, PMID 42385609, PMID 42407008, PMID 42431263
2023 (5), 2017 (1), 2018 (1)